Lapatinib Stada (Lapatinib)

Lapatinib blocks the intracellular tyrosine kinase activity of EGFR and HER2 receptors. This inhibition stops downstream signaling pathways that drive cell growth and survival, thereby slowing or stopping the proliferation of HER2‑driven cancer cells.

The specific dose of Lapatinib Stada is determined by the prescribing physician based on the patient’s clinical condition, treatment regimen, and other individual factors. Dosage instructions are provided on the prescription label.

Lapatinib’s safety in pregnancy and lactation has not been established. It is generally contraindicated in pregnant women, and breastfeeding is not recommended while on therapy. Women of child‑bearing potential should use effective contraception.

To order Lapatinib Stada, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Lapatinib is a small‑molecule tyrosine kinase inhibitor that targets both EGFR and HER2 intracellular domains, whereas agents like trastuzumab are monoclonal antibodies that bind the extracellular HER2 domain. Lapatinib can be combined with trastuzumab and chemotherapy for synergistic effects, offering an oral alternative to injectable biologics.

Lapatinib Stada should be stored at ambient temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and do not store in a bathroom or other humid environments.

Lapatinib Stada is taken orally, usually once daily, with or without food as directed by the prescriber. The tablet should be swallowed whole with a glass of water and not crushed or chewed.

Serious risks include liver toxicity, cardiac dysfunction (reduced left‑ventricular ejection fraction), severe skin reactions such as Stevens‑Johnson syndrome, interstitial lung disease, and QT‑interval prolongation, which can lead to dangerous heart rhythms.

Patients with known hypersensitivity to lapatinib or any of its excipients, those with uncontrolled cardiac disease, severe hepatic impairment, or who are pregnant should not use Lapatinib Stada. Clinicians should evaluate each patient’s medical history before initiating therapy.